Comparison of Glucagon Administered by Either the Nasal (LY900018) or Intra-muscular (GlucaGen) Routes in Adult Patients With Type 1 Diabetes Mellitus During Controlled Insulin-Induced Hypoglycemia
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Glucagon (Primary) ; Glucagon (Primary)
- Indications Hypoglycaemia
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 24 Jul 2019 Results presented in an Eli Lilly media release.
- 05 Oct 2018 Results of a primary efficacy analysis (n=66) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jan 2018 Status changed from recruiting to completed.